Drug And Alcohol Intervention
Merck Grants License to LabCorp for the Development of the test that could identify patients likely to respond to … Whitehouse Station, NJ Merck announced —- Today a nonexclusive license agreement with Laboratory Corporation of America Holdings ® for the marketing of genetic testing may help predict response of patients infected with hepatitis C to peginterferon alfa-based therapy.
Intervention host Ken Seeley talks drug and alcohol treatment
